公开(公告)号：US20230414750A1

公开(公告)日：2023-12-28

申请号：US18188168

申请日：2023-03-22

Applicant: Hoffmann-La Roche Inc. ,  Genentech, Inc.

Inventor： Maria FILIPPOU-FRYE ,  Joseph Nathaniel PAULSON ,  Leonardo ROQUE PEREIRA ,  Emily PICCIONE GRIFFIN ,  Stephen James SIMKO, III ,  Johanna SY ,  Akiko TAGAWA ,  Beate WULFF ,  Betsy Lane ALTHAUS ,  David CARLILE ,  Nassim DJEBLI

IPC: A61K39/395 ,  A61P35/00 ,  A61K31/664 ,  A61K31/282 ,  A61K31/7048 ,  A61K38/19 ,  A61K31/185 ,  A61K31/573 ,  A61K31/138 ,  A61K31/167 ,  C07K16/28

CPC classification number: A61K39/3955 ,  A61P35/00 ,  A61K31/664 ,  A61K31/282 ,  A61K31/7048 ,  A61K38/193 ,  A61K2039/545 ,  A61K31/573 ,  A61K31/138 ,  A61K31/167 ,  C07K16/2887 ,  C07K16/2809 ,  A61K31/185

Abstract: The present invention relates to methods of treating B-cell proliferative disorders, e.g., primary refractory or relapsed diffuse large B-cell lymphoma (DLBCL), by administering an anti-CD20/anti-CD3 bispecific antibody and in combination with an anti-CD20 antibody (e.g., obinutuzumab or rituximab) and one or more chemotherapeutic agents selected from ifosfamide, carboplatin, and/or etoposide.

公开(公告)号：US20220153842A1

公开(公告)日：2022-05-19

申请号：US17516979

申请日：2021-11-02

Applicant: Genentech, Inc.

Inventor： Chi-Chung LI ,  Carol Elaine O'HEAR ,  Stephen James SIMKO, III ,  Iris Tranthuyngan TO ,  Klara TOTPAL ,  Hong WANG ,  Michael C. WEI ,  Shen YIN ,  Brendan Christian BENDER ,  Xi CHEN ,  Yu-Waye CHU ,  Maria HRISTOPOULOS

IPC: C07K16/28 ,  C07K16/46 ,  A61K47/68 ,  A61P35/00

Abstract: The present invention relates to the treatment of subjects having CD20-positive cell proliferative disorders (e.g., B cell proliferative disorders, such as non-Hodgkin's lymphomas). More specifically, the invention pertains to the treatment of subjects having a CD20-positive cell proliferative disorder (e.g., B cell proliferative disorder) by administering a combination of an anti-CD20/anti-CD3 bispecific antibody and an anti-CD79b antibody drug conjugate.